Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3

Journal of Dermatological Science

Volumn 81, Issue 2, 2016, Pages 85-92

  Yang, Luting ^a   Li, Bing ^a   Dang, Erle ^a   Jin, Liang ^a   Fan, Xueli ^a   Wang, Gang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Pro inflammatory cytokines; Psoriasis; Regulatory T cells; STAT3

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 6; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; STAT3 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSORIASIS VULGARIS; REGULATORY T LYMPHOCYTE; RESPONDER T CELL; CASE CONTROL STUDY; CELL CULTURE; CELL PROLIFERATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PHENOTYPE; PHOSPHORYLATION; PSORIASIS; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PHENOTYPE; PHOSPHORYLATION; PSORIASIS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84957434789     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2015.11.007     Document Type: Article

References (33)

1. Reich A., Welz-Kubia K., Rams Ł. Apprehension of the disease by patients suffering from psoriasis. Adv. Dermatol. Allergol. 2014, 5:289-293.
2. Lew W., Bowcock A.M., Krueger J.G. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and Type 1 inflammatory gene expression. Trends Immunol. 2004, 25:295-305.
3. Ellis C.N., Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 2001, 345:248-255.
4. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 2006, 212:8-27.
5. Izcue A., Coombes J.L., Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu. Rev. Immunol. 2009, 27:313-338.
6. + regulatory T cells prevent type 1 diabetes preceded by dendritic cell-dominant invasive insulitis by affecting chemotaxis and local invasiveness of dendritic cells. J. Immunol. 2010, 185:2493-2501.
7. +CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 2005, 174:164-173.
8. Goodman W.A., Levine A.D., Massari J V., Sugiyama H., McCormick T.S., Cooper K.D. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J. Immunol. 2009, 183:3170-3176.
9. Leonard W.J., O'shea J.J. Jaks and STATs: biological implications. Annu. Rev. Immunol. 1998, 16:293-322.
10. Mertens C., Darnell J.E. SnapShot: JAK-STAT signaling. Cell 2007, 131.
11. Andrés R.M., Hald A., Johansen C., Kragballe K., Iversen L. Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity. Exp. Dermatol. 2013, 22:323-328.
12. Chen Z., Lin F., Gao Y., Li Z., Zhang J., Xing Y., et al. FOXP3 and RORgammat: transcriptional regulation of Treg and Th17. Int. Immunopharmacol. 2011, 11:536-542.
13. Xu L., Kitani A., Stuelten C., McGrady G., Fuss I., Strober W. Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. Immunity 2010, 33:313-325.
14. Boca A.N., Talamonti M., Galluzzo M., Botti E., Vesa Ş C., Chimenti S., et al. Genetic variations in IL6 and IL12B decreasing the risk for psoriasis. Immunol. Lett. 2013, 156:127-131.
15. Mease P.J. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr. Opin. Rheumatol. 2015, 27:127-133.
16. He Z., Jin L., Liu Z.-F., Hu L., Dang E.-L., Feng Z.-Z., et al. Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis. Br. J. Dermatol. 2012, 167:191-193.
17. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Müller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
18. Costanzo A., Chimenti M.S., Botti E., Caruso R., Sarra M., Monteleone G. IL-21 in the pathogenesis and treatment of skin diseases. J. Dermatol. Sci. 2010, 60:61-66.
19. Wang K., Zhang H., Kugathasan S., Annese V., Bradfield J.P., Russell R.K., et al. diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn disease. Am. J. Hum. Genet. 2009, 84:399-405.
20. Goodman W.A., Young A.B., McCormick T.S., Cooper K.D., Levine A.D. Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J Immunol 2011, 186:3336-3345.
21. Rodriguez R.S., Pauli M., Neuhaus I., Al E. Memory regulatory T cells reside in human skin. J. Clin. Invest. 2014, 124:1027-1036.
22. + Treg cell accumulation and correlated with psoriasis disease severity. Clin. Immunol. 2010, 135:108-117.
23. Koenen H.J.P.M., Smeets R.L., Vink P.M., van Rijssen E., Boots A.M.H., Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008, 112:2340-2352.
24. + regulatory T. cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J. Invest. Dermatol. 2011, 131:1853-1860.
25. + regulatory T cells in human autoimmune disease. Nat. Med. 2011, 17:673-675.
26. McClymont S.A., Putnam A.L., Lee M.R., Esensten J.H., Liu W., Hulme M.A., et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J. Immunol. 2011, 186:3918-3926.
27. + T lymphocytes. Cell. Signal. 2007, 19:806-816.
28. Che Mat N.F., Zhang X., Guzzo C., Gee K. Interleukin-23-induced interleukin-23 receptor subunit expression is mediated by the janus kinase/signal transducer and activation of transcription pathway in human CD4 T cells. J. Interferon Cytokine Res. 2011, 31:363-371.
29. + regulatory T cells in antitumor immune response. J. Immunol. 2005, 175:4433-4440.
30. Gaffen S.L. An overview of IL-17 function and signaling. Cytokine 2008, 43:402-407.
31. Sano S., Chan K.S., DiGiovanni J. Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases. J. Dermatol. Sci. 2008, 50:1-14.
32. Sano S., Chan K.S., Carbajal S., Clifford J., Peavey M., Kiguchi K., et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 2005, 11:43-49.
33. Miyoshi K., Takaishi M., Nakajima K., Ikeda M., Kanda T., Tarutani M., et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J. Invest. Dermatol. 2011, 131:108-117.